This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CINC CinCor Pharma (CINC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About CinCor Pharma Stock (NASDAQ:CINC) 30 days 90 days 365 days Advanced Chart Get CinCor Pharma alerts:Sign Up Key Stats Today's Range$29.02▼$29.3550-Day Range$28.73▼$29.5652-Week Range$10.53▼$43.15Volume6.35 million shsAverage Volume818,447 shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.Read More… Receive CINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CinCor Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CINC Stock News HeadlinesFormer CinCor execs raise $3.8M for new Cincinnati biopharma firmJanuary 28, 2025 | bizjournals.comCinRx Pharma portfolio company CinDome raises $40M toward Series B roundMay 28, 2024 | bizjournals.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 10, 2025 | Porter & Company (Ad)DelveInsight Business Research, LLP: Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsightApril 26, 2024 | finanznachrichten.deGlobal Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsightApril 26, 2024 | tmcnet.comCinCor Pharma Inc.March 22, 2024 | thestreet.comPurdue Pharma to plead guilty in $8bn opioid settlementDecember 12, 2023 | bbc.comImpel Pharmaceuticals hit by another C-suite departureDecember 6, 2023 | bizjournals.comSee More Headlines CINC Stock Analysis - Frequently Asked Questions When did CinCor Pharma IPO? CinCor Pharma (CINC) raised $176 million in an initial public offering on the week of November 7th 2022. The company issued 11,000,000 shares at $15.00-$17.00 per share. What other stocks do shareholders of CinCor Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that CinCor Pharma investors own include ARMOUR Residential REIT (ARR), AstraZeneca (AZN), AGNC Investment (AGNC), Amgen (AMGN), Broadcom (AVGO), Costco Wholesale (COST) and Cisco Systems (CSCO). Company Calendar Today5/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CINC CIK1868734 Webwww.cincor.com Phone844-531-1834FaxN/AEmployees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($17.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.03% Return on Assets-27.21% Debt Debt-to-Equity RatioN/A Current Ratio51.96 Quick Ratio51.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.74) per share Price / Book-16.70Miscellaneous Outstanding Shares43,760,000Free Float36,937,000Market Cap$1.27 billion OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CINC) was last updated on 5/10/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Remember when they said crypto would never go mainstream? Well, something remarkable has happened… Blac...Crypto 101 Media | SponsoredThis robot is coming to 65 million Americans … this year.The Robotics Revolution has arrived. And not surprisingly, Nvidia is leading the way. Nvidia CEO Jensen ...Weiss Ratings | SponsoredTrump’s Secret WeaponWall Street is nervous. Billionaires are shifting assets. And everyday investors? Most are completely unprepa...American Alternative | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredMAY 14: New IPO 350X Bigger Than Amazon IPO?The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, Ma...Paradigm Press | SponsoredOne Stock Gold Blueprint to Survive the Market ChaosOne Stock Gold Blueprint to Survive the Market Chaos Markets are volatile, uncertainty is everywhere, and A...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CinCor Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CinCor Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
